Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2016, Vol. 43 Issue (2): 198-202    DOI: 10.12891/ceog3078.2016
Original Research Previous articles | Next articles
Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women
D. Carati1, *(), A. Zizza2, M. Guido3, A. De Donno3, R. Stefanizzi1, R. Serra4, I. Romano4, C. Ouedraogo5, M. Megha6, A. Tinelli7
1Research & Development Department, Ekuberg Pharma srl, Martano
2Institute of Clinical Physiology, National Research Council, Lecce
3Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, Faculty of Sciences, University of Salento, Lecce
4Department of Diabetology, Poliambulatory “Cittadella della Salute”, Lecce (Italy)
5Department of Obstetrics and Gynecology, Teaching Hospital of Ouagadougou, Ouagadougou (Burkina Faso)
6Laboratory of Clinical Pathology, Poliambulatory “Cittadella della Salute” Lecce
7Department of Obstetrics and Gynecology, Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Vito Fazzi Hospital, Lecce (Italy)
Download:  PDF(137KB)  ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Problems affecting the vaginal tract in diabetic women are very often neglected. The efficacy and safety of three gynecological treatments in diabetic women have been assessed. Materials and Methods: A single-blind randomized progressive trial on 48 diabetic women affected by vaginal dryness, dyspareunia, and recurrent Candida infections was carried out. The ICIQ Vaginal Symptoms (ICIQ-VS) questionnaire was administered. Results: The analysis of the parameters of ICIQ-VS questionnaire among the three groups showed significant difference only for “dragging pain” (p = 0.019) and “soreness” (p = 0.028). In all groups and for all parameters of the questionnaire, improvement of symptoms was observed. In particular, in Group 1 for all symptoms a highly significant difference was observed, to support the already known benefits of the products and of the proposed combination. Significant improvement was also observed in Group 2. Conclusions: The proposed treatment with DermoXENR Ultracalming Special for diabetics and DermoXEN R Vitexyl vaginal gel exert effective moisturizing and soothing action. Indeed, the aforementioned products have been proven effective for the main gynecological problems of diabetic women.
Key words:  Diabetes      vulvovaginal discharge      Vaginal dryness      Dermoxen®      Candida Albicans     
Published:  10 April 2016     
*Corresponding Author(s):  D. CARATI     E-mail:  davide.carati@ekubergpharma.com

Cite this article: 

D. Carati, A. Zizza, M. Guido, A. De Donno, R. Stefanizzi, R. Serra, I. Romano, C. Ouedraogo, M. Megha, A. Tinelli. Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(2): 198-202.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3078.2016     OR     https://ceog.imrpress.com/EN/Y2016/V43/I2/198

[1] Zhu Chen, Hui Huang, Jingcen Hu, Shuyu Wang, Liang Xia. Circulating neutrophil gelatinase-associated lipocalin and gestational diabetes mellitus: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1206-1214.
[2] Elisa Casella, Carla Ettore, Ferdinando Antonio Gulino, Elisa Pappalardo, Filippo Rapisarda, Stella Capriglione, Giuseppe Ettore. Two successful pregnancies after a simultaneous kidney and pancreas transplantation for type 1 diabetes mellitus-complicated nephropathy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 697-699.
[3] Guo-Lin Liu, Ning-Zhi Zhang. Routine blood tests in early pregnancy: their development and value in the early diagnosis of gestational diabetes mellitus[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 228-233.
[4] N. Al-Husban, A. Hababeh, M. Al-Kasasbeh, R. Odeh, M. Shaheen, D. Moughrabi, D. Zabalawi. Thyroid stimulating hormone (TSH) level variations in early pregnancy and feto-maternal outcome; retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 675-680.
[5] C. Ji, L.J. Sun, L.T. Li, J. Ma, W.H. Ge, X. Zhao. Impact of clinical pharmacist intervention on blood glucose control and perinatal outcomes in gestational diabetes mellitus through a diabetes management system[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 645-652.
[6] J. A. Villarreal-Rodriguez, L. G. Mancillas Adame, J. Maldonado-Sanchez, A. Guzmán-López, O. R. Treviño-Montemayor, J. G. Gonzalez-Gonzalez, D. Saldívar-Rodríguez. A randomized controlled trial comparing acarbose vs. insulin therapy for gestational diabetes in individuals with inadequate glycemic control by diet alone[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 552-555.
[7] H.J. Wang, T.H. Chou, Y.C. Lee, H.K. Au. Acute fatty liver during pregnancy and gestational diabetes insipidus: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 438-441.
[8] Hongying Zhang, Qingling Wei, Jinlan Wei, Haiyang Pang, Wenxuan Wei, Yu Sun, Mengya He, Yanling Sun. Importance of diagnosis time on pregnancy outcomes in pregnant women with pre-gestational diabetes mellitus[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 57-61.
[9] L. Yuanmei, Z. Qian, X. Fengsen, W. Yankui. Restricted gestational weight gain in overweight/obese women with gestational diabetes mellitus and pregnancy outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 763-769.
[10] M. Trisovic, O. Mladenovic, J. Bila, K. Lalić, D. Kisic Tepavcevic. The predictive value of metabolic syndrome in the evaluation of pregnancy course and outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 776-778.
[11] Y. Aydin, S. Uludağ, A. Atis, S. Uludağ, S. Ilvan. Leukemia inhibitory factor, glycodelin, and HOXA-10 in gestational diabetes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 539-541.
[12] J. Chollet, L. A. Meyn, F. Mermelstein. Weekly vaginal administration of tamoxifen for three months in postmenopausal women with vulvar and vaginal atrophy: a possible new treatment approach?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 285-288.
[13] Y. Huo, S.-X. Liu, L. Li, J. Feng, H.-Y. Li, G.-Y. Song. Circulating vaspin and IL-6 concentrations in second trimester pregnancy with gestational diabetes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 211-215.
[14] J. Agah, F. Roodsarabi, A. Manzuri, M. Amirpour, A. Hosseinzadeh. Prevalence and associated risk factors of gestational diabetes mellitus in a tertiary hospital in Iran[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 85-89.
[15] R. Garcia Rodriguez, B. Vega Guedes, R. Garcia Delgado, L. Obreros Zegarra, Y. Emergui Zhrizen, C. Cabrera GarcÁa, M. Medina Castellano, J.Á. Garcia Hernández. Prenatal diagnosis of femoral hypoplasia-unusual facies syndrome associated to sacral hemivertebra[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 131-135.
No Suggested Reading articles found!